Liquid Biopsy Promising for Surveillance of Tumor Changes

Video

In this video we discuss a large-scale genomic analysis that found that patterns of genetic changes detected in circulating tumor DNA mirror those identified in tumor tissue biopsies.

A large-scale genomic analysis has found that patterns of genetic changes detected in circulating tumor DNA mirror those identified in tumor tissue biopsies. The study looked at blood samples from more than 15,000 patients and 50 different tumor types and paired them with nearly 400 tissue biopsies that had undergone genetic testing.

Results of the study (abstract 11501) were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago. Here, Philip C. Mack, PhD, of the University of California Davis Comprehensive Cancer Center, who presented the data at the meeting, discusses results of the analysis.

Related Videos
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer
Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center,
Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.
Related Content